Medical Physicist at St George Cancer Center, Sydney. Special interest in brachytherapy. Opinions are my own and not the views of my employer
Joined September 2019
- Tweets 1,420
- Following 422
- Followers 587
- Likes 4,082
154 Photos and videos
May 24
Fantastic long term data for HDR boost. Very interesting to see lower side effect profile for TRUS based over CT based planning. More confidence in contouring or greater certainty in needle positioning at time of treatment? @agomeziturriaga @KamravaMD
¡Otro gran trabajo en #ESTRO2026! Compartimos los resultados a largo plazo de la braquiterapia HDR boost en cáncer de próstata (TC based vs TRUS). Datos robustos con más de 10 años de seguimiento medio que avalan un excelente control y supervivencia de los pacientes.
3
5
881
May 10
Happy to share that the first manuscript from the ENCOMPASS prostate brachytherapy consortium has now been published in @BrachyJournal
sciencedirect.com/science/ar…
@PBlanchardMD @MarioTerlizziFR @agomeziturriaga @DrAmanTaggar @ArjitB_medphys
1
5
12
595
May 10
This type of work is helping inform the development of larger international collaborative initiatives under ENCOMPASS, focused on outcomes, workflows, imaging, dosimetry, and quality assurance in prostate brachytherapy.
1
2
68
May 10
Huge thank you to all collaborators, participating institutions, and international brachytherapy societies who helped distribute and support the survey.
Publication available here:
authors.elsevier.com/sd/arti…
#Brachytherapy #RadiationOncology #MedicalPhysics #RadOnc
2
82
Feb 25
I do wonder for these IR patients getting brachytherapy that LDR is a better option. Our institutional BCR are lower than what’s been reported. Of course this is also single site - our ENCOMPASS consortium is working on a prospective registry to collect this data internationally
We've applied to pool data from our site and NRG 0232 (LDR /- EBRT) and 0538 (SBRT arm). Stay tuned!
1
242
Feb 25
This is the type of data we need! Really hope to get this off the ground in Australia
For unfavourable risk prostate cancer, @CDNCancerTrials #PR24 is accruing and is just about to randomize patient 200!
1
262
Feb 25
Congratulations @cristian_udo and co-authors on putting this together.
Hard to take too much away given the differences in how toxicity was collected amongst SBRT studies and only 1 brachytherapy trial included from single site.
We need more data before making conclusions
Curious about whether #SBRT or #brachy is better treatment for intermediate risk prostate cancer?
See @cristian_udo @JAMANetworkOpen article just posted!
JAMANetworkOpen.2026;9(2):e260146. doi:10.1001/jamanetworkopen.2026.0146
@DrSpratticus @AmarUKishan @nickva1 @alison_tree
2
1
5
3,066
Feb 24
The trick now is determining how to contour, plan, and QA these cases efficiently and economically.
Feb 21
Phase 3 randomized trial of SRS v HA-WBRT meets its primary endpoint. jamanetwork.com/journals/jam…
2
1
7
1,072
Feb 24
Looking forward to updating on the progress of our ENCOMPASS prostate brachytherapy registry initiative.
Don't miss our special session on genitourinary cancers at #TROG2026ASM next month. Researchers including @weeloonong & @JPoderMedPhys will give updates on innovative new research into radiotherapy for prostate & bladder cancers.
Register today: ap1.hubs.ly/y0BZwq0
1
3
263
Joel Poder retweeted
Dr Jennifer Chard, Radiation Oncologist, shares why she loves her work and the extraordinary privilege of meeting so many remarkable individuals through their cancer journeys.
ow.ly/g1p750Y7V7P
#UnitedByUnique #WorldCancerDay #TargetingCancer
3
3
179
Joel Poder retweeted
Radiation Oncologist Dr Gina Hesselberg highlights the importance of equitable, patient‑centred care and the power of a strong multidisciplinary team.
Watch here >> ow.ly/VBg350Y7mfG
#TargetingCancer #WorldCancerDay #UnitedByUnique
3
5
155
Jan 24
I’ve been asked to attempt to provide some advice on re-irradiation using brachytherapy at this upcoming ESTRO webinar. No promises.
📢 Reirradiation Webinar
Combining Brachytherapy with EBRT
🗓 3 Feb 2026 | 15:00–16:00 CET | Online
The 5th session supporting safe and effective reRT clinical decision-making.
👉 Register: bit.ly/49AN7GL
🔗 Series overview: bit.ly/3JuqEkg
#Radonc
2
231
Joel Poder retweeted
9 Nov 2025
DON’T MISS OUT! Applications now open for interprofessional Foundations of Leadership in Radiation Oncology #FLIRO course held w @ESTRO_RT ASM Stockholm 2026. Places strictly limited.
Apply at: estro.org/Courses/2026/Found…
@caro_acro_ca @RANZCRcollege #RadOnc
2
5
1,226
Joel Poder retweeted
Notable article: October 2025 #MedicalPhysics
AAPM task group 317 report: A joint AAPM and ESTRO report on brachytherapy catheter, needle, and applicator tracking technology
Please join us in congratulating Luc Beaulieu et al whose article was selected.
aapm.onlinelibrary.wiley.com…
3
3
360
14 Oct 2025
Key diff in my mind is that in E2E testing we can identify a point on MRI, register to CT and than use IGRT to find point with 3D error < 1 mm.
However, could we do that with an RO contoured volume in a patient dataset … prob not.
Does it seem to matter? …Also prob not
1
6
1,759
Joel Poder retweeted
7 Oct 2025
ICYMI, 5 weeks left to Register!
Details & links here: wix.to/t5bDlzs
2
4
420
11 Sep 2025
In settings where MRI availability is low, this would be a game changer
10 Sep 2025
🚨Biparametric MRI (no contrast) is noninferior to multiparametric MRI for detecting clinically significant #prostatecancer 🚨
📢 PRIME trial in @JAMA_current
⭐️RCT of 490 patients w/ suspicion of prostate cancer
➡️ Shorter scans
➡️ Lower cost
➡️ Similar accuracy
Potential new global standard 🌍🚨
🔗shorturl.at/6Fb2s
@PCFnews @urotoday @UrologyTimes @renalandurology @UroOnc
1
310